Royalty Pharma plc - Ordinary Shares - Class A
RPRX
Get informed when a big investor buys or sells
+ FollowEarnings Call Q1 2026
May 6, 2026 - AI Summary
Exclusive for Stockcircle Pro members
Sign up
Current Fair Value
105.6% upsideUndervalued by 105.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $23.98 Billion |
|---|---|
| Enterprise Value | $32.35 Billion |
| Dividend Yield | $0.91 (1.63%) |
| Earnings per Share | $2.33 |
| Beta | 0.4 |
| Outstanding Shares | 431,887,000 |
Return
| Return on Equity | 12.01% |
|---|---|
| Return on Assets | 4.18% |
| Return on Invested Capital | 8.48% |
Valuation & Multiples
| P/E Ratio | 29.1 |
|---|---|
| PEG | 122.43 |
| Price to Sales | 10.99 |
| Price to Book Ratio | 2.39 |
| Enterprise Value to Revenue | 13.25 |
| Enterprise Value to EBIT | 19.8 |
| Enterprise Value to Net Income | 39 |
| Total Debt to Enterprise | 0.28 |
| Debt to Equity | 1.3 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3400▼ 26.20% |
|---|---|
| Total Calls | 720,400▲ 222.90% |
| Total Puts | 244,900▲ 82.35% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 82.50%▼ 0.72% |
|---|---|
| Total Invested | $16.94B▲ 22.45% |
| Investors Holding | 591▲ 47.00% |
ESG Score
No data
About Royalty Pharma plc
Relevant Senate Committees
Provides the analysis for tax legislation; Royalty Pharma’s business is highly sensitive to the tax treatment of royalty income and international corporate structures.
Most critical committee; oversees Medicare/Medicaid and drug pricing legislation (e.g., Inflation Reduction Act), which directly impacts royalty revenue streams.
Determines funding levels for the NIH and FDA, which drive the drug development pipeline and the regulatory speed of approval for royalty-bearing products.
Oversees the FDA and the drug approval process. Any regulatory change here directly affects the viability and value of the drug royalties RPRX acquires.
Directly oversees intellectual property, patents, and antitrust laws, which are the fundamental legal pillars of Royalty Pharma's business model.
This committee frequently investigates drug pricing and pharmaceutical industry practices, creating significant headline risk and pressure on the drugs RPRX depends on.